Successful treatment of chronic hepatitis B and D with pegylated-interferon plus entecavir
Journal
Journal of the Formosan Medical Association
Journal Volume
114
Journal Issue
11
Pages
1140-1141
Date Issued
2015
Author(s)
Abstract
Interferon-based regimen has been used to treat hepatitis D virus (HDV) super-infection on top of hepatitis B virus (HBV) carriers; however, viral relapse is frequent after stopping therapy. Recently, quantitative hepatitis B surface antigen (qHBsAg) was introduced to help the management of chronic hepatitis B (CHB). Little is known about its role in the treatment of HBV and HDV dual infection. Herein, we reported a 45-year-old male HBV carrier with HDV co-infection who received combination therapy of pegylated-interferon α-2a plus entecavir. The qHBsAg level was adopted as the treatment guidance and a consolidation therapy of 12 months was continued after HBsAg loss. The patient achieved HBsAg seroconversion with HDV RNA undetectable after 35 months of combination therapy and sustained therapeutic response 12 months post-therapy. Therefore, personalized response-guided therapy by using qHBsAg may be an option for the treatment for HBV and HDV dual infection. ? 2013.
SDGs
Other Subjects
entecavir; hepatitis B surface antigen; peginterferon alpha2a; virus RNA; alpha interferon; antivirus agent; entecavir; guanine; hepatitis B surface antigen; macrogol derivative; peginterferon alpha2a; recombinant protein; virus DNA; adult; alanine aminotransferase blood level; antiviral therapy; Article; case report; chronic hepatitis; chronic hepatitis B; chronic hepatitis d; human; inflammation; liver fibrosis; liver histology; male; mixed infection; qualitative analysis; seroconversion; treatment duration; treatment response; analogs and derivatives; blood; combination drug therapy; complication; Hepatitis B, Chronic; Hepatitis D, Chronic; liver cirrhosis; middle aged; pathology; treatment outcome; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Hepatitis D, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Treatment Outcome
Publisher
Elsevier
Type
journal article